February 2026 in “Annals of Case Reports” Tofacitinib helped a patient regrow hair after 40 years of total hair loss.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
17 citations
,
January 2010 in “Acta Dermato Venereologica” EGFR inhibitors can cause yellowish skin eruptions.
May 2025 in “Life Studies” Lung cancer patients on immunotherapy and chemotherapy often experience severe fatigue, drowsiness, and appetite loss.
1 citations
,
December 2023 in “Nanomaterials” Combining specific nanoparticles with immune therapy significantly improves cancer treatment.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking TYK2 might be a new way to treat hair loss from alopecia areata.
July 2003 in “Journal of Cutaneous Medicine and Surgery” Some medications can improve skin conditions, while lifestyle factors like smoking and drinking may worsen them; treatments like monoclonal antibodies and imiquimod cream show promise for certain skin diseases.
October 2024 in “Dermatologica Sinica” Recognizing unusual symptoms in Crohn's disease is crucial for proper treatment.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
March 2026 in “European journal of ecology, biology and agriculture.” Patients with alopecia areata have higher levels of certain immune markers, suggesting new treatment targets.
Tofacitinib helped a woman with total-body hair loss grow her hair back.
Permanent micropigmentation can help cancer survivors feel better about themselves by restoring eyebrows lost during chemotherapy.
March 2023 in “Clinical, cosmetic and investigational dermatology” IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
April 2007 in “Nature Clinical Practice Urology” TICE salvage chemotherapy is effective for treating germ-cell tumors with poor prognosis.
1 citations
,
July 2025 in “Journal of Investigative Dermatology” IL-27 may help prevent hair loss by creating immune-suppressing cells.
9 citations
,
April 2010 in “Lung cancer” Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.
November 2025 in “JEADV Clinical Practice” Leflunomide may lower alopecia areata risk, while other immunomodulators might increase it.
5 citations
,
April 2025 in “Journal of Cosmetic Dermatology” Janus kinase inhibitors are effective and safe for treating Alopecia Areata.
JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.
Patients and doctors often agree on the severity of eyebrow and eyelash hair loss in severe alopecia areata.
Inhibiting mTORC2 can reduce DNA repair and increase cancer cell death, suggesting potential for targeted brain cancer treatments.
Baricitinib is more effective than methotrexate for severe alopecia areata.
September 2025 in “Value in Health” January 2013 in “대한피부과학회지” Gefitinib can cause rare scarring hair loss.
34 citations
,
August 2002 in “British Journal of Dermatology” ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.
28 citations
,
February 2007 in “Cancer Research” Blocking certain proteins in mouse skin can reduce and shrink skin tumors.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
2 citations
,
May 2011 in “Journal of Clinical Oncology” Further testing of paclitaxel poliglumex for this cancer treatment is not justified.
February 2017 in “Cancer Research” Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
5 citations
,
July 2024 in “Journal of Microbiology and Biotechnology” ICP5249 helps hair grow by activating a specific cell pathway.